KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Interest Expenses (2023 - 2025)

Historic Interest Expenses for Travere Therapeutics (TVTX) over the last 9 years, with Q3 2025 value amounting to $2.8 million.

  • Travere Therapeutics' Interest Expenses changed 0.0% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.3 million, marking a year-over-year increase of 111.4%. This contributed to the annual value of $11.2 million for FY2024, which is 118.23% down from last year.
  • According to the latest figures from Q3 2025, Travere Therapeutics' Interest Expenses is $2.8 million, which was down 0.0% from $2.8 million recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Interest Expenses registered a high of $2.9 million during Q1 2025, and its lowest value of $2.8 million during Q1 2024.
  • Over the past 3 years, Travere Therapeutics' median Interest Expenses value was $2.8 million (recorded in 2023), while the average stood at $2.8 million.
  • Its Interest Expenses has fluctuated over the past 5 years, first tumbled by 151.25% in 2024, then soared by 357.14% in 2025.
  • Over the past 3 years, Travere Therapeutics' Interest Expenses (Quarter) stood at $2.8 million in 2023, then fell by 0.74% to $2.8 million in 2024, then changed by 0.0% to $2.8 million in 2025.
  • Its Interest Expenses was $2.8 million in Q3 2025, compared to $2.8 million in Q2 2025 and $2.9 million in Q1 2025.